Oral MK2 Inhibitor Composition for Inflammatory Pathway Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory conditions do not effectively target the underlying inflammatory pathways, particularly the MK2 pathway, leading to inadequate therapeutic outcomes.
Innovation Solution
Administering an oral dose of 5 mg/day to 300 mg/day of Compound I or its derivatives, formulated in a pharmaceutical composition with a pharmaceutically acceptable carrier, to inhibit MK2 activity and modulate inflammatory signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory conditions are used, then they are administered to patients, but they do not effectively target the underlying inflammatory pathways leading to inadequate therapeutic outcomes
Solution Approach 1:
The patent changes the molecular target parameter from generic anti-inflammatory pathways to specifically the MK2 pathway. Compound I is designed with specific molecular characteristics that enable it to selectively inhibit MK2, a key component of the p38 MAPK inflammatory pathway, thereby improving therapeutic reliability through precise pathway targeting.
Solution Approach 2:
The patent introduces Compound I as an intermediary substance that mediates the inhibition between the administered drug and the MK2 pathway. This compound acts as a selective inhibitor that bridges the gap between general anti-inflammatory treatment and specific pathway targeting, enabling effective therapeutic intervention through MK2 inhibition.
2Reliability
If oral compositions of Compound I are administered at doses of 5 mg/day to 300 mg/day, then MK2 activity is inhibited and inflammatory markers are reduced, but the composition requires formulation with pharmaceutically acceptable carriers
Solution Approach 1:
The patent uses pharmaceutically acceptable carriers as intermediary substances that facilitate the delivery of Compound I without interfering with its biological activity. These carriers mediate between the active compound and the administration route, enabling oral delivery while maintaining the compound's efficacy in inhibiting MK2 and reducing inflammatory markers.
Solution Approach 2:
The patent optimizes the dosage parameter of Compound I to a range of 5 mg/day to 300 mg/day, which provides effective MK2 inhibition while managing the complexity of pharmaceutical formulation. This dosage range is calibrated to achieve therapeutic effects with reasonable formulation requirements.
Data Source
AI summary
The present disclosure relates to oral compositions of Compound I or a derivative thereof. Methods of use for treating an inflammatory condition are also disclosed.